Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells

Journal of Neurochemistry

Volumn 113, Issue 6, 2010, Pages 1621-1631

  Li, Yazhou ^a   Tweedie, David ^a,b   Mattson, Mark P ^a   Holloway, Harold W ^a   Greig, Nigel H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

6 hydroxydopamine; Exendin 4; Glucagon like peptide 1; Neuroprotection; Oxidative stress; Parkinson's disease

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; OXIDOPAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2;

ARTICLE; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NERVE CELL CULTURE; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 4; ADRENERGIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BROMODEOXYURIDINE; BUTADIENES; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FORSKOLIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYDROGEN PEROXIDE; HYPOGLYCEMIC AGENTS; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; NITRILES; OXIDANTS; OXIDOPAMINE; PEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VENOMS;

ANIMALIA;

EID: 77953094551     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06731.x     Document Type: Article

References (31)

1. Albani D., Polito L., Batelli S. et al. (2009) The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem. 110, 1445 1456.
2. Baggio L. Drucker D. (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131 2157.
3. Banks W. A., Uchida D., Arimura A., Somogyvári-Vigh A. Shioda S. (1996) Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. Ann. N Y Acad. Sci. 805, 270 277.
4. Banks W. A., Goulet M., Rusche J. R., Niehoff M. L. Boismenu R. (2002) Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse. J. Pharmacol. Exp. Ther. 302, 1062 1069.
5. Bertilsson G., Patrone C., Zachrisson O. et al. (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86, 326 338.
6. Dejda A., Sokołowska P. Nowak J. (2005) Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol. Rep. 57, 307 320.
7. Drucker D. Nauck M. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696 1705.
8. Fasano M., Alberio T., Colapinto M., Mila S. Lopiano L. (2008) Proteomics as a tool to investigate cell models for dopamine toxicity. Parkinsonism Relat. Disord. 14 (Suppl 2 S135 S138.
9. Gault V. Hölscher C. (2008) GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur. J. Pharmacol. 587, 112 117.
10. Halliwell B. (2006) Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97, 1634 1658.
11. Hamilton A. Holscher C. (2009) Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport. 20, 1161 1166.
12. Hanrott K., Gudmunsen L., O'Neill M. Wonnacott S. (2006) 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 281, 5373 5382.
13. Harding H., Zhang Y., Bertolotti A., Zeng H. Ron D. (2000) Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol. Cell 5, 897 904.
14. Harkavyi A., Abuirmeileh A., Lever R., Kingsbury A., Biggs C. Whitton P. (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation 5, 19.
15. Kolterman O., Kim D., Shen L., Ruggles J., Nielsen L., Fineman M. Baron A. (2005) Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 62, 173 181. (Pubitemid 40674548)
16. Li Y., Hansotia T., Yusta B., Ris F., Halban P. Drucker D. (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278, 471 478.
17. Li Y., Perry T., Kindy M. et al. (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl Acad. Sci. USA 106, 1285 1290.
18. Li Y., Duffy K., Ottinger M. et al. (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 19, 1205 1219.
19. Liang S., Zhang W., McGrath B., Zhang P. Cavener D. (2006) PERK (eIF2alpha kinase) is required to activate the stress-activated MAPKs and induce the expression of immediate-early genes upon disruption of ER calcium homoeostasis. Biochem. J. 393, 201 209.
20. Malhotra J. Kaufman R. (2007) Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid. Redox Signal. 9, 2277 2293.
21. Perry T. Greig N. (2004) A new Alzheimer's disease interventive strategy: GLP-1. Curr. Drug Targets 5, 565 571.
22. Perry T., Haughey N., Mattson M., Egan J. Greig N. (2002a) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 302, 881 888.
23. Perry T., Lahiri D., Chen D., Zhou J., Shaw K., Egan J. Greig N. (2002b) A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958 966.
24. Perry T., Lahiri D., Sambamurti K., Chen D., Mattson M., Egan J. Greig N. (2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 72, 603 612.
25. Perry T., Holloway H., Weerasuriya A., Mouton P., Duffy K., Mattison J. Greig N. (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 203, 293 301.
26. Reddy V., Zhu X., Perry G. Smith M. (2009) Oxidative stress in diabetes and Alzheimer's disease. J. Alzheimers Dis. 16, 763 774.
27. Sultana R. Butterfield D. (2009) Role of oxidative stress in the progression of Alzheimer's disease. J. Alzheimers Dis. 19, 341 353.
28. Ulrich C. N., Holtmann M. Miller L. (1998) Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. Gastroenterology 114, 382 397.
29. Valko M., Leibfritz D., Moncol J., Cronin M., Mazur M. Telser J. (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39, 44 84.
30. Yusta B., Baggio L., Estall J., Koehler J., Holland D., Li H., Pipeleers D., Ling Z. Drucker D. (2006) GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 4, 391 406.
31. Zander M., Madsbad S., Madsen J. Holst J. (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824 830.